Study #2023-0691
A phase 1b/2, open-label umbrella study to evaluate safety and efficacy of Elacestrant in various combinations in patients with Metastatic Breast Cancer (ELEVATE)
MD Anderson Study Status
Enrolling
Treatment Agent
Elacestrant, Alpelisib, Everolimus, Ribociclib, Abemaciclib, Palbociclib, Capivasertib
Description
This is a multicenter, Phase 1b/2 trial in participants with estrogen receptor positive/human epidermal growth factor receptor 2 negative (ER+/HER2-) advanced/metastatic breast cancer. The phase 1b part of the trial will determine the recommended Phase 2 dose (RP2D) of elacestrant when administered in combination with alpelisib, everolimus, palbociclib, capivasertib, and ribociclib. The Phase 2 part of the trial will evaluate the efficacy and safety of the various combinations.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Breast Cancer, Metastatic Breast Cancer
Study phase:
Physician name:
Vicente Valero
Department:
Breast Medical Oncology
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.